Clinical trial
Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C
NCT00298714 · Hospital Clinic of Barcelona, Other · Completed
Key facts
| NCT number | NCT00298714 |
|---|---|
| Title | Effects of Losartan on Hepatic Fibrogenesis in Chronic Hepatitis C |
| Official title | Effect of Long-Term Administration of Oral Losartan on Hepatic Fibrogenesis and Gene Expression in Chronic Hepatitis C With Significant Liver Fibrosis. |
| Lead sponsor | Hospital Clinic of Barcelona, Other |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C, Liver Fibrosis |
| Intervention type | Drug |
| Interventions | Losartan |
| Enrollment | 20 |
| Start date | Mar 1, 2003 |
| Completion | Jan 1, 2006 |
| First posted | Mar 3, 2006 |
| Last update posted | Nov 22, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: